Trust crucial to treatment interruption
At the Australasian HIV/AIDS Conference, Dr Gordon Campbell discussed participant motivations and experiences from an HIV cure clinical trial with treatment interruption (ATI). Dr Campbell interviewed participants from the TITAN study. All were satisfied with their experience and most felt well during the study. Trust in the clinical research team was crucial to their participation and peace-of-mind. They would participate in future ATI trials. Support for the HIV community was a primary reason for participation. Other motivations were an interest in cure science, curiosity about their immune system, and optimism for improved treatment or cure.
These findings show that ATI trials can proceed with HIV community support and will guide future ATI trials.